Christopher Sullivan
2022
In 2022, Christopher Sullivan earned a total compensation of $768.5K as Chief Financial Officer and principal financial officer at Avalo Therapeutics, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $72,800 |
|---|---|
| Option Awards | $301,614 |
| Salary | $344,135 |
| Other | $50,000 |
| Total | $768,549 |
Sullivan received $344.1K in salary, accounting for 45% of the total pay in 2022.
Sullivan also received $72.8K in non-equity incentive plan, $301.6K in option awards and $50K in other compensation.
Rankings
In 2022, Christopher Sullivan's compensation ranked 3,582nd out of 5,753 executives tracked by ExecPay. In other words, Sullivan earned more than 37.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,582 out of 5,753 | 38th |
Division Manufacturing | 2,035 out of 3,133 | 35th |
Major group Chemicals And Allied Products | 975 out of 1,419 | 31st |
Industry group Drugs | 912 out of 1,320 | 31st |
Industry Pharmaceutical Preparations | 665 out of 966 | 31st |
Source: SEC filing on October 19, 2023.
Sullivan's colleagues
We found three more compensation records of executives who worked with Christopher Sullivan at Avalo Therapeutics in 2022.